Please login to the form below
Hydroxychloroquine
This page shows the latest Hydroxychloroquine news and features for those working in and with pharma, biotech and healthcare.
WHO to test three more potential COVID-19 treatments
Last year, WHO announced that four drugs tested in its Solidarity trial, touted as effective treatments for severe COVID-19 infection – remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon – had little or no ... Hydroxychloroquine and
Latest news
-
WHO trial casts doubt on remdesivir's efficacy
The interim results, published on the pre-print server medRxiv, showed that remdesivir, along with hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have ‘little or no effect’ on 28-day
-
Pearls of wisdom
Hydroxychloroquine does not work. Ingestion of disinfectants, hand sanitiser and light into the body do not work either.
-
Speed kills
On 22 May, The Lancet published a research paper about hydroxychloroquine, the antimalarial drug, as a potential treatment for COVID-19. ... claimed that the use of hydroxychloroquine carried a greater risk of heart arrhythmia and death.
-
WHO takes stock of global COVID-19 R&D progress
The WHO also took the decision to discontinue the Solidarity Trial’s hydroxychloroquine and lopinavir/ritonavir arms following a review of evidence obtained at the interim analysis. ... These results showed that neither hydroxychloroquine nor
-
FDA grants emergency authorisation to chloroquine for COVID-19
This data supports earlier preliminary results from a small study of hydroxychloroquine in combination with the antibiotic azithromycin, and as a monotherapy. ... Although the drug was effective on its own, when added to the antibiotic azithromycin,
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
How will COVID-19 affect uptake of vaccinations against other diseases?
that halted hydroxychloroquine trials due to data inconsistencies, if repeated in the context of SARS-CoV-2 vaccines, risk undermining public confidence in vaccines.
-
COVID-19: the race to find a vaccine
Other antivirals including hydroxychloroquine – a drug championed by President Donald Trump – and favipiravir are also in clinical development, raising hopes that researchers will find a drug with some level of efficacy
-
As COVID-19 takes over the world, biopharma fights back
A standard malaria treatment: chloroquine and hydroxychloroquine. A decades-old antimalaria drug, chloroquine, entered the global spotlight in March after US President Donald Trump touted it as a potentially effective coronavirus ... treatment. Since then
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
